Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravuconazole Prophylaxis in Non-Myeloablative Allogeneic HSCT
NCT00064311Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ravuconazole in invasive fungal infection (IFI), sponsored by National Institutes of Health. Primary endpoint: Safety and tolerability of ravuconazole. Started Jun 2003; status: completed.
02
Drugs
ravuconazole
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT00064311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00064311.